UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For
the month of August 2026
Commission
file number: 001-41990
Mobile-health
Network Solutions
(Exact
name of registrant as specified in its charter)
2
Venture Drive, #07-08 Vision Exchange
Singapore
608526
+65
6222 5223
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form
40-F ☐
When
used in this Form 6-K, unless otherwise indicated, the terms “the Company,” “Mobile-Health,” “we,”
“us” and “our” refer to Mobile-health Network Solutions and its subsidiaries.
Entry
into Share Purchase Agreement
On
August 11, 2026, we entered into a share purchase agreement (the “Agreement”) with Jurong Day & Night Clinic Pte. Ltd.
(“JDNC”), a Singapore-incorporated company operating a licensed medical clinic in Singapore, and Ms. Ting Shih King (the
“Seller”), pursuant to which the Company agreed to acquire ordinary shares representing 19% of the issued and paid-up share
capital of JDNC (the “Sale Shares”).
The
purchase price of US$256,500 will be satisfied in full by the issuance to the Seller of 186,410 ordinary shares of the Company (the “Consideration
Shares”). The Consideration Shares will be issued in a private placement in reliance on Section 4(a)(2) of the Securities Act of
1933, as amended (the “Securities Act”), and/or Regulation S thereunder, will be “restricted securities” under
Rule 144, and will be subject to a contractual nine-month lock-up from the closing date. The Seller has been granted no registration
rights.
The
Seller will retain the remaining 81% of JDNC and full operating control, and the Company will not receive any board seat, board observer
right, or voting control over JDNC’s board of directors.
The
Agreement provides for a twelve-month performance period following closing, including completion of the integration of the Company’s
operating system at JDNC within nine months of closing. If the performance targets are not met, or if the Company fails to complete the
digital deployment of the software suite within nine months of closing, the Seller may, within two years from the closing date, repurchase
the Sale Shares by returning to the Company the exact number of Consideration Shares issued at closing, which the Company would cancel
or hold in treasury.
Closing
is subject to customary conditions precedent, including satisfactory due diligence, corporate approvals, Singapore healthcare regulatory
and other required approvals, and the Company’s submission of a Listing of Additional Shares notification to Nasdaq at least fifteen
calendar days prior to the issuance of the Consideration Shares.
The
foregoing description of the Agreement is a summary only and does not purport to be complete.
Forward-Looking
Statements
This
report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but
not limited to statements regarding the expected closing of the transaction and the anticipated integration of the Company’s systems.
These statements involve risks and uncertainties, including the risk that closing conditions are not satisfied, and actual results may
differ materially. The Company undertakes no obligation to update these statements except as required by law.
SIGNATURES
Pursuant
to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
| |
Mobile-health
Network Solutions |
| |
|
| Date:
August 12, 2026 |
By: |
/s/
Siaw Tung Yeng |
| |
|
Siaw
Tung Yeng |
| |
|
Co-Chief
Executive Officer |